Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetic kidney disease

Long-term lessons from EMPA-KIDNEY

Nature Reviews Nephrology volume 21, pages 222–223 (2025)Cite this article

Subjects

Sodium–glucose co-transporter 2 inhibitors have revolutionized the management of chronic kidney disease. However, long-term data regarding their use are lacking. The post-trial follow-up study to EMPA-KIDNEY provides several insights into how the effects of these powerful medications might be optimized, but several key questions remain unanswered.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rossing, P. et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 102, 990–999 (2022).

    Article  PubMed  Google Scholar 

  2. Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).

    Article  CAS  PubMed  Google Scholar 

  3. Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).

    Article  CAS  PubMed  Google Scholar 

  4. Herrington, W. G. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2023).

    Article  CAS  PubMed  Google Scholar 

  5. The EMPA-KIDNEY Collaborative Group. Long-term effects of empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2409183 (2024).

  6. United States Renal Data System. 2021 Annual Data Report. NIH https://usrds-adr.niddk.nih.gov/2021 (2021).

  7. Lamprea-Montealegre, J. A. et al. Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease. Diabetes Care 45, 2900–2906 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Malik, M. E. et al. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. Lancet Reg. Health Eur. 29, 100617 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  9. United States Renal Data System. Healthcare expenditures for persons with CKD. NIH https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd (2024).

  10. Herrington, W., Staplin, N., Agrawal, N. & Haynes, R. Long-term effects of empagliflozin in CKD (abstract FR-OR103). ASN Kidney Week, https://www.asn-online.org/education/kidneyweek/2024/program-abstract.aspx?controlId=4166148 (2024).

Download references

Author information

Authors and Affiliations

  1. Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia

    Lauren Heath & Carol Pollock

Authors
  1. Lauren Heath
    View author publications

    Search author on:PubMed Google Scholar

  2. Carol Pollock
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Carol Pollock.

Ethics declarations

Competing interests

C.P. has been on advisory boards and given lectures for Boehringer Ingelheim, Astra Zeneca and Janssen Cilag on the topic of sodium–glucose cotransporter 2 inhibitors. L.H. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heath, L., Pollock, C. Long-term lessons from EMPA-KIDNEY. Nat Rev Nephrol 21, 222–223 (2025). https://doi.org/10.1038/s41581-024-00921-2

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41581-024-00921-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing